STIFEL 2026 HEALTHCARE CONFERENCE - PYXIS ONCOLOGY INC

Based on the transcript provided, here is the extraction and summary of forward-looking statements regarding Pixis Biotherapeutics.

• Explicit Guidance:

  • OS Data Update: Guidance provided for an update on Overall Survival (OS) data in the first half of 2028 (referred to as "first half of next year" relative to the 2027 timeline mentioned).
  • Pivotal Trial Initiation: Aiming to dose the first patient on the pivotal Headliner trial in the middle part of 2027.
  • Frontline Combination Data: Expecting an update on the mikva (MICBO) + pembrolizumab (PEMBRO) frontline combination data before the end of 2027 (referred to as "end of this year" in the context of the 2027 timeline, though the transcript explicitly mentions "end of 2027" for the milestone).
  • Cash Runway: Current capitalization from 2026 fundraisings is sufficient to fund operations through the first half of 2028, extending well beyond the initiation of the Headliner trial.
  • Trial Control Arm Baseline: Management anticipates the current standard of care control arm will deliver 5–6 months of OS, serving as a benchmark to validate the trial design.

• Business-Segment Outlook:

  • Lead Asset (Mikva): The program is transitioning from Phase 2 dose expansion to a pivotal Phase 3 trial (Headliner) in second-line head and neck cancer.
  • Target Patient Population: Estimated total addressable market of 20,000 patients seeking second-line treatment; management projects 70% of the 30,000 annual new frontline patients will progress to second-line therapy.
  • Combination Therapy: Ongoing dose escalation in frontline settings with pembrolizumab (PEMBRO) at doses 3.6 mg and 4.4 mg; initial data expected before year-end 2027, with durability data in the second half of 2028.
  • Future Indications: Management is exploring life-cycle expansion into neoadjuvant/adjuvant locally advanced disease and other solid tumor types (specifically those expressing EDBFN), pending the success of the head and neck program.
  • Trial Design: The Headliner trial (Phase 3) is designed for 500 patients, randomized 1:1 to mikva vs. investigator choice of docetaxel, methotrexate, or cetuximab. Primary endpoints are Response Rate (ORR) and Overall Survival (OS).

• Market and Competitive Outlook:

  • Competitive Tailwinds: Anticipates that the potential approval of EGFR bispecifics in the frontline setting (potentially in 2028) will increase the unmet need in the second line by extending frontline PFS by 6–12 months, creating a larger pool of patients needing second-line options.
  • Standard of Care Shifts: Notes that the current standard of care in the US is shifting to platinum + PD-1, with a potential future shift to EGFR + PD-1; the trial is designed to accommodate both cohorts (platinum/PD-1 experienced and EGFR inhibitor experienced).
  • Differentiation: Management highlights a 94% Disease Control Rate (DCR) and rapid response times (2/3 of patients respond by 6 weeks) as key differentiators over existing options like docetaxel/cetuximab, particularly for HPV-negative patients with limited options.
  • Impact of AMIVANE: Expects J&J's AMIVANE (anti-EGFR) to have little immediate impact on the pivotal trial design or survival curves, as the trial is set to start before widespread commercial adoption affects the patient pool.

• Macro / Industry Outlook:

  • Regulatory Pathway: Plans to conclude FDA Project Optimist requirements (dose-finding for ADCs) by the end of 2027, utilizing data from 30+ patients at 5.04 mg (with dose cap) and 20+ patients at 3.6 mg.
  • Geographic Scope: The Headliner trial is designed as a global study to accommodate varying standard of care landscapes (e.g., US vs. international options for the control arm).

• Strategic Initiatives:

  • Phase 3 Launch: Execution of the Headliner pivotal trial, aiming to start enrollment in mid-2027.
  • Dose Optimization: Implementation of a dose cap/modified weight-based dosing (capped at 5.04 mg/kg) to reduce toxicity (specifically peripheral neuropathy) while maintaining efficacy; 5.04 mg dose is the preferred candidate for Phase 3.
  • Capital Deployment: Utilizing 2026 fundraising proceeds to sustain operations through mid-2028 to cover the pivotal trial initiation and data readout.
  • Data Presentations: Presentation of late-breaking abstract data by MD Anderson investigators at the TRiPLA meeting in Barcelona to support the 2027 trial roadmap.

• Risks and Headwinds to Outlook:

  • Safety Concerns: Potential for peripheral neuropathy, ocular toxicity, and pneumonitis/cutaneous issues associated with the auristatin payload, though efficacy of the dose cap has mitigated discontinuation rates.
  • Data Maturity: OS data is currently early (only 6 events at cut); reliance on the durability of the signal through first half of 2028 remains a critical risk factor for de-risking the trial.
  • Line of Therapy Sensitivity: Response rates may decline in later lines of therapy (e.g., 45% in 2nd line vs. 35% in 3rd line).
  • Regulatory Uncertainty: Final confirmation of the Phase 3 trial design and statistical plan is contingent on the outcome of the End of Phase 2 meeting and the successful completion of Project Optimist.
  • Competitive Dynamics: Potential delays or changes in the approval timeline of frontline EGFR bispecifics could alter the patient recruitment window and the competitive landscape for second-line therapy.

• Management Tone on the Future:

  • Confidence Level: High. Management expresses strong confidence in the efficacy profile (36% ORR, 94% DCR) and the safety profile post-dose capping, stating they have "exactly what we needed" to proceed to pivotal.
  • Strategic Focus: Highly focused on delivery and execution of the second-line head and neck program as the primary near-term value driver before evaluating other indications.
  • Forward-Looking Statement: Describes the upcoming OS data update as a "really important de-risking moment" and views the current data as "the best data set ever produced post-EGFR in head and neck cancer."

• Miscellaneous:

  • Financial Context: Mention of two successful fundraisings in 2026 by "thoughtful investors" providing a robust balance sheet position relative to the company's development stage.
  • Target Mechanism: Emphasis on the unique target EDB fibronectin (EDBFN), which is present in almost all solid tumors but absent in normal tissue, suggesting broad potential beyond head and neck cancer.